



## THE PREVALENCE, ISOLATION, AND ANTIMICROBIAL SUSCEPTIBILITY TESTING OF ENTEROCOCCUS SPECIES FROM VARIOUS CLINICAL SAMPLES IN A TERTIARY CARE HOSPITAL

PREVALENSI, ISOLASI, DAN UJI KEPEKAAN ANTIMIKROBA PADA SPESIES ENTEROCOCCUS DARI BERBAGAI SAMPEL KLINIS DI RUMAH SAKIT PERAWATAN TERSIER

Turin Afroz<sup>ORCID</sup>

Instructor, Department of Microbiology, Bangladesh University of Health Sciences, Dhaka, Bangladesh

Original Research Article  
Penelitian

### ABSTRACT

**Background:** *Enterococcus* is routinely considered a low-grade pathogen. The synergistic action of *Enterococci* with other bacteria increases the risk of infection. *Enterococci* are currently the next most common cause of healthcare-associated infections after *E. coli*. Greater understanding is needed regarding *Enterococcus* stress survival, virulence, and resistance patterns to assess the complexity of disease-causing *Enterococcus*. **Purpose:** Analyze the prevalence of *Enterococcus* and assess the antibiotic sensitivity pattern of *Enterococcus*. **Method:** A descriptive cross-sectional study was designed and carried out in the Department of Microbiology at Bangladesh University of Health Sciences, Dhaka, over a period of 3 months. Bacterial culture and sensitivity were the methods employed for microbiological examination. **Result:** A total of 558 bacterial strains were isolated, among which the growth of *Enterococcus* spp. was 27 (4.83%). The prevalence of *Enterococcus* spp. among different samples was 4.83%. The number of highly sensitive strains ranged from 66.66% to 77.77% for antibiotics, namely gentamycin, ampicillin, amoxicillin, and meropenem. Moderately high sensitivity to levofloxacin (29.62%) and low sensitivity to doxycycline (14.81%) were also analyzed. **Conclusion:** The study recommends that antibiotics should be used after proper laboratory procedures are undertaken and it should be selected based on antimicrobial susceptibility tests.

### ARTICLE INFO

Received 03 November 2023  
Revised 07 November 2023  
Accepted 20 January 2024  
Available online 05 March 2024

Correspondence:  
Turin Afroz

E-mail:  
[turinafroze007@gmail.com](mailto:turinafroze007@gmail.com)

**Keywords:**  
*Enterococcus* species, Prevalence,  
Susceptibility testing

### ABSTRAK

**Latar belakang:** *Enterococcus* merupakan patogen yang dianggap tingkat rendah. Tindakan sinergis *Enterococci* dengan bakteri lain dapat meningkatkan risiko infeksi. Saat ini, *Enterococci* merupakan penyebab paling umum dari infeksi di layanan kesehatan setelah *E. coli*. Pemahaman yang lebih luas mengenai kelangsungan hidup, virulensi, dan pola resistensi *Enterococcus* diperlukan untuk menilai kompleksitas penyakit yang disebabkan oleh *Enterococcus*. **Tujuan:** Menganalisis prevalensi dan menilai uji kepekaan antibiotik pada *Enterococcus*. Metode: Penelitian ini menggunakan metode deskriptif *cross-sectional* yang dilakukan di Departemen Mikrobiologi, Ilmu Kesehatan Universitas Bangladesh, Dhaka, selama jangka waktu 3 bulan. Pemeriksaan mikrobiologi dilakukan dengan metode kultur dan uji kepekaan bakteri. **Hasil:** Sebanyak 558 strain bakteri berhasil diisolasi dan menghasilkan pertumbuhan *Enterococcus* spp. sebesar 27 (4,83%). Prevalensi *Enterococcus* spp. pada sampel yang berbeda sebesar 4,83%. Jumlah strain yang sangat sensitif pada antibiotik gentamisin, ampisilin, amoksisilin, dan meropenem berkisar antara 66,66% sampai 77,77%. Selain itu, juga dianalisis sensitivitas pada levofloxacin (29,62%) yang memiliki sensitivitas cukup tinggi dan doksisisiklin (14,81%) dengan sensitivitas rendah. **Kesimpulan:** Penelitian ini merekomendasikan penggunaan antibiotik dapat dilakukan setelah melakukan prosedur laboratorium yang tepat dan harus dipilih berdasarkan uji kepekaan antimikroba.

**Kata kunci:**  
Spesies *Enterococcus*, Prevalensi,  
Uji kepekaan



## INTRODUCTION

*Enterococci* are normal inhabitants of the gastrointestinal tract and biliary tracts of humans and animals (Huycke *et al.*, 1998; Kwit *et al.*, 2023). Sometimes, they are present in small numbers in the vagina and male urethra. The synergistic action of *Enterococci* with other bacteria increases infection (Afonina *et al.*, 2018; Seputiene *et al.*, 2012; Zaheer *et al.*, 2020). Urinary tract infections are the most common periodic infections resulting from *Enterococcus* (Marino *et al.*, 2021; Mishra *et al.*, 2022). Post-surgery wound infections rank second. *Enterococcus* is routinely considered a low-grade pathogen. The capability of *Enterococcus* species to survive in a range of unfavorable environments permits numerous paths of cross-contamination of *Enterococci* in human disease (Zaheer *et al.*, 2020), combining those from food, environmental (Ferguson *et al.*, 2013; Kim *et al.*, 2022; Monteiro *et al.*, 2023), and hospital sources (Kwit *et al.*, 2023; Ramos *et al.*, 2020). The bacteria have come into view as an expanding and significant cause of nosocomial infection in recent decades (Hufnagel *et al.*, 2004; Spengler *et al.*, 2009; Yadav *et al.*, 2017). *Enterococci* are currently the next most familiar source for healthcare-associated infections after *E.coli* (Govindarajan *et al.*, 2022; Billington *et al.*, 2014; Marino *et al.*, 2021; Esmail *et al.*, 2019). They exhibit both intrinsic and acquired resistance to antibiotics (Hollenbeck and Rice, 2012; Yoshino, 2023). Acquired resistance in *Enterococci* occurs either through mutations in DNA or through the acquisition of new DNA (Coombs *et al.*, 2014; Yadav *et al.*, 2017). Resistance to a broad range of antibiotics enhances the emergence of *Enterococci* as a cause of nosocomial infection (Tuncay and Sancak, 2022). Greater understanding is needed regarding *Enterococcus* stress survival, virulence, and resistance patterns to assess the complexity of disease-causing *Enterococcus* (Kim *et al.*, 2022; Miller *et al.*, 2014). The virulence factors that increase pathogenicity not only appear in increasing numbers among various clinical isolates but are also associated with more severe clinical presentations (Seputiene *et al.*, 2012).

Therefore, the involvement of certain *Enterococcus* traits in virulence is proven by a greater incidence in nosocomial isolates. Significant control of multiple drug-resistant *Enterococcus* requires better contact isolation in hospitals along with the patient care environment, sensible use of antibiotics, and continuous surveillance. Overall, this study aims to analyze the prevalence of *Enterococcus* and assess the antibiotic sensitivity pattern of *Enterococcus*. The expected impact of the study results from various factors influencing the prevalence of *Enterococcus* with corresponding recommendations.

## MATERIAL AND METHOD

A descriptive cross-sectional study was designed and carried out in the Department of Microbiology at Bangladesh University of Health Sciences, Dhaka, Bangladesh, for three months. The study population included patients attending both the *Outpatient Department (OPD)* and *Inpatient Department (IPD)* of a general hospital who consented to participate in the study.

This research was conducted on pus and urine samples. Pathogens in pus specimens are the causative agents of infectious diseases affecting the skin, liver, lungs, brain, eyes, and joint cavities. Urine samples can also help in the early detection of serious diseases such as kidney disease, diabetes, liver disease, and urinary tract infections. Bacterial culture and sensitivity was the microbiological examination method. The research instruments included analytical balance, autoclave, hot air oven, incubator, laminar airflow, wire loop etc. Data regarding age and gender were collected, and categorical and numerical data were summarized using numbers, frequencies, and percentages.

### Examination of specimen

Collection and transport of pus and urine: Special care was taken to avoid contaminating the specimen with commensal organisms from the skin before an antiseptic dressing was applied by using a sterile technique, up to 5 mL of pus from a drainage tube was collected and transferred to a leak-proof container.

The first midstream urine passed by the patient at the beginning of the day was collected for examination. The specimen was the most concentrated and therefore the most suitable for culture, microscopy, and biochemical analysis. A sterile, dry, wide-necked, leak-proof container was given to the patient to collect a 10 - 20 mL specimen. The container was labeled with the date, the patient's name and number, and the time of collection.

### Culture

On the first day, specimens were cultured on Blood and MacConkey agar immediately after collecting the sample and incubated for 18-24 hours at 37°C. Gram staining was performed, and a routine examination of urine revealed a probable number of pus cells. On the second day, the media were examined for colony morphology. Catalase and coagulase tests were performed for growth on blood agar, with *Staphylococcus aureus* testing positive for both catalase and coagulase tested positive. Motility indole urease, triple sugar iron, Cimon citrate, and oxidase test were performed for growth on MacConkey. *E.coli* was identified as citrate-negative and motile. *Klebsiella* spp. was identified as citrate-positive and non-motile. *Pseudomonas* spp. was identified as oxidase test positive. *Proteus* was urease

and indole positive. *Acinetobacter* spp. was lactose-fermenting, catalase-positive, non-motile, oxidase-negative, and aerobic gram-negative coccobacilli characteristics. *Citrobacter* spp. was identified as catalase, citrate, H<sub>2</sub>S, motility positive, and indole-negative. *Enterococci*, growth on blood agar was found with circular colonies of 1-2 mm in diameter, and there was no growth on MacConkey. *Enterococci* are gram-positive bacteria stirring as pairs or short chains (Namikawa et al., 2017). A catalase test was performed. In the case of a catalase negative result, the bile esculin test, growth in 6.5% NaCl with trypticase soy broth and bacitracin sensitivity biochemical tests were performed. On the third day, the results of the biochemical tests were analyzed. *Enterococcus* was identified as gram-positive cocci in chains, catalase-negative, bile esculin-positive, and growth in trypticase soy broth with 6.5% NaCl (Mishra et al., 2022).

Antimicrobial susceptibility testing was carried out using modified Kirby-Bauer disc diffusion techniques, as recommended by the Clinical and Laboratory Standard Institute. The turbidity of the suspension was assessed in comparison with 0.5 McFarland standards. Mueller-Hinton agar plates were used for the antimicrobial susceptibility test. The antimicrobial-impregnated disks of ampicillin, amoxicillin, cefixime, ceftriaxone, ceftazidime, cefuroxime, gentamicin, doxycycline, levofloxacin, and meropenem were placed using sterile forceps, positioned away from each other to avoid overlapping zones of inhibition. Interpretation was performed according to the manufacturer's guidelines. The categorization of sensitivity or resistance to antibiotics was done based on a range of zones of inhibition. The specific range for each antibiotic was as follows: ampicillin (disk potency -10 microgram, susceptibility  $\geq 17$ , resistant  $\leq 13$ ), amoxicillin (disk potency -20 microgram, susceptibility  $\geq 18$ , resistant  $\leq 13$ ), cefixime (disk potency -5 microgram, susceptibility  $\geq 19$ , resistant  $\leq 15$ ), ceftriaxone (disk potency -30 microgram, susceptibility  $\geq 27$ , resistant  $\leq 24$ ), ceftazidime (disk potency -30 microgram, susceptibility  $\geq 18$ , Resistant  $\leq 14$ ), cefuroxime (disk potency -30 microgram, susceptibility  $\geq 18$ , resistant  $\leq 14$ ), gentamicin (disk potency -120 microgram, susceptibility  $\geq 15$ , resistant  $\leq 12$ ), doxycycline (disk potency -30 microgram, susceptibility  $\geq 16$ , resistant  $\leq 12$ ), levofloxacin (disk potency -5 microgram, susceptibility  $\geq 19$ , resistant  $\leq 15$ ), and meropenem (disk potency -10 microgram, susceptibility  $\geq 16$ , resistant  $\leq 13$ ).

## RESULT

Demographic data collected based on gender and age are shown in Tables 1 and 2. Among the participants, 10 (37%) were male, and 17 (63%) were female. The ages of the participants were categorized into three groups (0 - 20, 20 - 40, >40). The highest number of participants, both male and female, belonged to the >40 years group.

**Table 1.** Gender distribution of the participants

Gender	Frequency	Percentage (%)
Female	17	63
Male	10	37
<b>Total</b>	<b>27</b>	<b>100</b>

**Table 2.** Age groups of the participants

Age	Female	Percentage (%)	Male	Percentage (%)
0 - 20	1	5.9	1	10
20 - 40	2	11.76	0	0
>40	14	82.35	9	90
<b>Total</b>	<b>17</b>	<b>100</b>	<b>10</b>	<b>100</b>

Table 3 demonstrates that a total of 558 bacterial strains were isolated, with the predominant isolate being *E. coli*, accounting for 196 (35.12%) of the total. This was followed by *Klebsiella* spp. at 132 (23.65%), *Staphylococcus aureus* at 70 (12.54%), *Pseudomonas* spp. at 62 (11.11%), *Proteus* spp. at 35 (6.27%), *Enterococcus* spp. at 27 (4.83%), *Citrobacter* at 25 (4.48%), and *Acinetobacter* spp. at 11 (1.97%).

**Table 3.** Pattern of bacteria isolated (n = 558)

Bacteria	Number	Percentage (%)
<i>E. coli</i>	196	35.12
<i>Klebsiella</i> spp.	132	23.65
<i>Pseudomonas</i> spp.	62	11.11
<i>Enterococcus</i> spp.	27	4.83
<i>Staphylococcus aureus</i>	70	12.54
<i>Proteus</i>	35	6.27
<i>Acinetobacter</i> spp.	11	1.97
<i>Citrobacter</i> spp.	25	4.48
<b>Total</b>	<b>558</b>	<b>100</b>

Table 4 demonstrates that out of 558 organisms, *Enterococcus* spp. was 27 (4.83%). Sixty percent of *Enterococcus* was isolated from the pus sample. The highest number of isolates was from pus with 16 (60%) similar to what Sreeja et al. (2012) reported.

**Table 4.** Number and percentage of *Enterococcus* spp. identified from different samples

Sample	Number	Percentage (%)
Urine	11	40
Pus	16	60
<b>Total</b>	<b>27</b>	<b>100</b>

The prevalence of *Enterococcus* spp. was calculated as  $(27/558) \times 100 = 4.83\%$ . The antimicrobial sensitivity patterns of the isolates are shown in Table 5. The number of highly sensitive strains, ranging from 66.66% to 77.77% – namely gentamycin, ampicillin, amoxicillin, meropenem – was analyzed. Additionally, moderately high sensitivity to levofloxacin (29.62%) and low sensitivity to doxycycline (14.81%) were examined.

**Table 5.** Antimicrobial susceptibility pattern of different drugs (n =27)

Antibiotic	Sensitive (number)	Percentage (%)
Ampicillin	20	74.07
Amoxicillin	21	77.77
Ceftriaxone	0	0
Cefixime	0	0
Cefuroxime	0	0
Ceftazidime	0	0
Doxycycline	4	14.81
Gentamycin	18	66.66
Levofloxacin	8	29.62
Meropenem	21	77.77

## DISCUSSION

A total of 558 bacterial strains were isolated, with *Enterococcus* spp. accounting for 27 (4.83%) of them. Most of the participants were in the >40 age group, with the predominant age range being 40 - 60 (Billington *et al.*, 2014). The higher infection rate among the elderly (37.03% for males and 62.96% for females) was attributed to older individuals having increased exposure to the external environment, coupled with a history of receiving treatment from various healthcare facilities (Moghimbeigi *et al.*, 2018). This history served as a source for transmitting the infection. Shifts in the frequency of *Enterococcus* populations can arise from mutable changes in environmental conditions over time as a result of antibiotic treatment that delineates individual selective settings in hospitals (Tedim *et al.*, 2015; Horner *et al.*, 2021). Moreover, immunity tends to decrease with age, facilitating the colonization of these bacteria (Hufnagel *et al.*, 2004). In developing countries like Bangladesh, females usually receive treatment from government healthcare settings due to lower cost. This was the main reason for achieving the higher Enterococcal infection rate among females. However, anatomically, females are more prone to development.

The epidemiology of Enterococci is not implicit as prominent differences exist among species of resistant isolates originating from numerous geographic locations. The present study demonstrates that the prevalence of *Enterococcus* spp. among different samples was 4.83%, which surpasses the rates reported in India (2.3%), Ethiopia (3.5%), and the Asia-Pacific region (3.6%) (Ferede *et al.*, 2018; Low *et al.*, 2001; Paul *et al.*, 2017). The percentages of isolates showing extreme sensitivity ranged from 66.66% to 77.77%, specifically to gentamycin, ampicillin, amoxicillin, and meropenem. Moderate high sensitivity to levofloxacin (29.62%) and low sensitivity to doxycycline (14.81%) were also investigated can be seen in Table 6.

**Table 6.** Percentage of antimicrobial agent sensitivity in different studies

Antimicrobial Agent	Present study	Ferede <i>et al.</i> (2018)	Paul <i>et al.</i> (2017)	Low <i>et al.</i> (2001)
Ampicillin	74.07%	20%	21.5%	60%
Gentamycin	66.66%	40%	55.8%	60%
Doxycycline	14.81%	26.7%	-	40%

The comparison of antimicrobial susceptibility testing in this study with other previous studies is presented in Table 6. High-sensitivity ampicillin showed 74.07% susceptibility, similar to the research of Low *et al.* (2001), who reported 60% susceptibility in the Asia-Pacific region. On the other hand, the studies by Ferede *et al.* (2018) and Paul *et al.* (2017) analyzed 20% and 21.5% susceptibility, respectively. The susceptibility of gentamycin was 66.66%, showing similarity to the studies by Paul *et al.* (2017) and Low *et al.* (2001), where their susceptibility rates were 55.8% and 60%, respectively. Once again, the susceptibility of doxycycline was 14.81%, indicating low sensitivity. This did not align with the findings of Low *et al.* (2001) at 40% for the Asia-Pacific region but was similar to the research by Ferede *et al.* (2018) at 26.7%.

The findings of the present study recommend that antibiotics should be used after undertaking proper laboratory procedures, and should be selected based on antimicrobial susceptibility tests. Antibiotics should be prescribed depending on experience and adjusted or changed according to the susceptibility report. It should also be recalled that certain drugs should be reserved and used only in cases of treatment failure. Continuous surveillance of all other drugs should be performed on drug-resistant proportions (Sabouni *et al.*, 2016, Siddig *et al.*, 2022). Resistance against cefixime, ceftazidime, and ceftriaxone has increased (Ahmed *et al.*, 2020 Siddig *et al.*, 2022). Currently, the first-line drugs ampicillin, amoxicillin, and meropenem are convenient but should be given after a proper culture sensitivity test (Yoshino, 2023).



## CONCLUSION

The observations of the present study are very concerning for developing countries such as Bangladesh. The first limitation of this study is the small sample size. Second, the findings are not generalizable at all times due to the short research period. These limitations present a new platform for further research. In the future, research will try to determine *Enterococcus*'s stress survival pattern to assess the complexity of disease-causing *Enterococcus*. It was challenging to collect data from participants.

## ACKNOWLEDGMENTS

The author would like to thank the Department of Microbiology, Bangladesh University of Health Sciences, Dhaka, Bangladesh. Proper permission was taken from the Department of Microbiology concerned for the study. Informed consent was obtained from participants along with a declaration of confidentiality and anonymity. The author did not receive any type of funding for this study. The author has no conflicts of interest to declare.

## REFERENCE

- Afonina, I., Lim, X.N., Tan, R., Kline, K.A., 2018. Planktonic Interference and Biofilm Alliance between Aggregation Substance and Endocarditis- and Biofilm-Associated Pili in *Enterococcus faecalis*. *J Bacteriol* Vol. 200(24), Pp. e00361-18.
- Ahmed, M.U., Asna, S.Z.H., Mahbub, A., 2020. Prevalence and Drug Resistance Status of *Enterococcus* in Tertiary Care Hospital. *AIBM* Vol. 16(1), Pp. 1-5.
- Billington, E.O., Phang, S.H., Gregson, D.B., Pitout, J.D.D., Ross, T., Church, D.L., Laupland, K.B., Parkins, M.D., 2014. Incidence, risk factors, and outcomes for *Enterococcus* spp. Blood Stream Infections: A Population-Based Study. *Int J Infect Dis* Vol. 26, Pp. 76-82.
- Coombs, G.W., Pearson, J.C., Daley, D.A., Le, T., Robinson, O.J., Gottlieb, T., Howden, B.P., Johnson, P.D.R., Bennett, C.M., Stinear, T.P., Turnidge, J.D., Australian Group on Antimicrobial Resistance, 2014. Molecular Epidemiology of Enterococcal Bacteremia in Australia. *J Clin Microbiol* Vol 52(3), Pp. 897-905.
- Esmail, M.A.M., Abdulghany, H.M., Khairy, R.M., 2019. Prevalence of Multidrug-Resistant *Enterococcus faecalis* in Hospital-Acquired Surgical Wound Infections and Bacteremia: Concomitant Analysis of Antimicrobial Resistance Genes. *Infect Dis (Auckl)* Vol. 12, Pp. 1178633719882929.
- Ferede, Z.T., Tullu, K.D., Derese, S.G., Yeshanew, A.G., 2018. Prevalence and Antimicrobial Susceptibility Pattern of *Enterococcus* Species Isolated from Different Clinical Samples at Black Lion Specialized Teaching Hospital, Addis Ababa, Ethiopia. *BMC Research Notes* Vol. 11(1), Pp. 793.
- Ferguson, D.M., Griffith, J.F., McGee, C.D., Weisberg, S.B., Hagedorn, C., 2013. Comparison of *Enterococcus* Species Diversity in Marine Water and Wastewater using Enterolert and EPA Method 1600. *J Environ Public Health* Vol. 2013, Pp. 848049.
- Govindarajan, D.K., Meghanathan, Y., Sivaramakrishnan, M., Kothandan, R., Muthusamy, A., Seviour, T.W., Kandaswamy, K., 2022. *Enterococcus faecalis* Thrives in Dual-Species Biofilm Models under Iron-Rich Conditions. *Archives of Microbiology* Vol. 206(710).
- Horner, C., Mushtaq, S., Allen, M., Hope, R., Gerver, S., Longshaw, C., Reynolds, R., Woodford, N., Livermore, D.M., 2021. Replacement of *Enterococcus faecalis* by *Enterococcus faecium* as The Predominant *Enterococcus* in UK Bacteraemias. *JAC Antimicrob Resist* Vol. 3(4), Pp. dlab185.
- Hollenbeck, B.L., Rice, L.B., 2012. Intrinsic and Acquired Resistance Mechanisms in *Enterococcus*. *Virulence* Vol. 3(5), Pp. 421-433.
- Hufnagel, M., Hancock, L.E., Koch, S., Theilacker, C., Gilmore, M.S., Huebner, J., 2004. Serological and Genetic Diversity of Capsular Polysaccharides in *Enterococcus faecalis*. *Journal of Clinical Microbiology* Vol. 42(6).
- Huycke, M.M., Sahm, D.F., Gilmore, M.S., 1998. Multiple-Drug Resistant *Enterococci*: The Nature of The Problem and An Agenda for The Future. *Emerg Infect Dis* Vol. 4(2), Pp. 239-249.
- Kim, Y., Choi, S.-I., Jeong, Y., Kang, C.-H., 2022. Evaluation of Safety and Probiotic Potential of *Enterococcus faecalis* MG5206 and *Enterococcus faecium* MG5232 Isolated from Kimchi, a Korean Fermented Cabbage. *Microorganisms* Vol. 10(10), Pp. 2070.
- Kwit, R., Zając, M., Śmiałowska-Węglińska, A., Skarżyńska, M., Bomba, A., Lalak, A., Skrzypiec, E., Wojdat, D., Koza, W., Mikos-Wojewoda, E., Pasim, P., Skóra, M., Polak, M., Wiącek, J., Wasyl, D., 2023. Prevalence of *Enterococcus* spp. and the Whole-Genome Characteristics of *Enterococcus faecium* and *Enterococcus faecalis* Strains Isolated from Free-Living Birds in Poland. *Pathogens* Vol. 12(6), Pp. 836.

- Low, D.E., Keller, N., Barth, A., Jones, R.N., 2001. Clinical Prevalence, Antimicrobial Susceptibility, and Geographic Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997–1999. *Clinical Infectious Diseases* Vol. 32(Supp.2), Pp. S133-S145.
- Marino, A., Munafò, A., Zagami, A., Ceccarelli, M., Di Mauro, R., Cantarella, G., Bernardini, R., Nunnari, G., Cacopardo, B., 2021. Ampicillin Plus Ceftriaxone Regimen against *Enterococcus faecalis* Endocarditis: A Literature Review. *J Clin Med* Vol. 10(19), Pp. 4594.
- Miller, W.R., Munita, J.M., Arias, C.A., 2014. Mechanisms of Antibiotic Resistance in Enterococci. *Expert Review Anti Infective Therapy* Vol. 12(10), Pp.1221-1236.
- Mishra, M., Sharma, D., Chauhan, D., 2022. Prevalence and Antibiotic Resistance Pattern of Isolated *Enterococcus* by Standard Techniques. *International Journal of Health Sciences and Research* Vol. 12(11), Pp. 7-11.
- Moghimbeigi, A., Moghimbeygi, M., Dousti, M., Kiani, F., Sayehmiri, F., Sadeghifard, N., Nazari, A., 2018. Prevalence of Vancomycin Resistance among Isolates of Enterococci in Iran: A Systematic Review and Meta-Analysis. *AHMT* Vol. 9, Pp. 177-188.
- Monteiro Marques, J., Coelho, M., Santana, A.R., Pinto, D., Semedo-Lemsaddek, T., 2023. Dissemination of Enterococcal Genetic Lineages: A One Health Perspective. *Antibiotics (Basel)* Vol. 12(7), Pp. 1140.
- Namikawa, H., Yamada, K., Shibata, W., Fujimoto, H., Takizawa, E., Niki, Makoto, Nakaie, K., Nakamura, Y., Oinuma, K.-I., Niki, Mamiko, Takemoto, Y., Kaneko, Y., Shuto, T., Kakeya, H., 2017. Clinical Characteristics and Low Susceptibility to Daptomycin in *Enterococcus faecium* Bacteremia. *The Tohoku Journal of Experimental Medicine* Vol. 243(3), Pp. 211-218.
- Paul, M., Nirwan, P.S., Srivastava, P., 2017. Isolation of *Enterococcus* from Various Clinical Samples and Their Antimicrobial Susceptibility Pattern in a Tertiary Care Hospital. *Int.J.Curr.Microbiol.App.Sci* Vol. 6(2), Pp. 1326-1332.
- Ramos, S., Silva, V., Dapkevicius, M. de L.E., Igrejas, G., Poeta, P., 2020. Enterococci, from Harmless Bacteria to a Pathogen. *Microorganisms* Vol.8(8), Pp. 1118.
- Sabouni, F., Pourakbari, B., Aghdam, M.K., Mahmoudi, S., Ashtiani, M.T.H., Movahedi, Z., Alyari, A.E., Sadeghi, R.H., MAMISHI, S., 2012. High Frequency of Vancomycin-Resistant *Enterococcus faecalis* in an Iranian Referral Children Medical Hospital. *Maedica (Bucur)* Vol. 7(3), Pp. 201-204.
- Siddig, L., Hamid, O., Elhadi, N., Bayoumi, M., 2022. Prevalence and Antimicrobial Profile of Colonized *Enterococcus* Species Isolated from Hospitalized and Non-hospitalized Patients. *American Journal of Infectious Diseases and Microbiology* Vol. 10(4), Pp. 119-123.
- Seputiene, V., Bogdaite, A., Ruzauskas, M., Suziedeliene, E., 2012. Antibiotic Resistance Genes and Virulence Factors in *Enterococcus faecium* and *Enterococcus faecalis* from Diseased Farm Animals: Pigs, Cattle and Poultry. *Pol J Vet Sci* Vol.15(3), Pp. 431-438.
- Spengler, G., Martins, A., Schelz, Z., Rodrigues, L., Aagaard, L., Martins, M., Costa, S.S., Couto, I., Viveiros, M., Fanning, S., Kristiansen, J.E., Molnar, J., Amaral, L., 2009. Characterization of Intrinsic Efflux Activity of *Enterococcus faecalis* ATCC29212 by A Semi-Automated Ethidium Bromide Method. *In Vivo* Vol. 23(1), Pp. 81-87.
- Sreeja, S., Babu P R, S., Prathab, A.G., 2012. The Prevalence and The Characterization of The *Enterococcus* Species from Various Clinical Samples in A Tertiary Care Hospital. *J Clin Diagn Res* Vol. 6(9), Pp. 1486-1488.
- Tedim, A.P., Ruiz-Garbajosa, P., Corander, J., Rodríguez, C.M., Cantón, R., Willems, R.J., Baquero, F., Coque, T.M., 2015. Population Biology of Intestinal *Enterococcus* Isolates From Hospitalized and Nonhospitalized Individuals in Different Age Groups. *Appl Environ Microbiol* Vol. 81(5), Pp. 1820-1831.
- Tuncay, R.M., Sancak, Y.C., 2022. The Prevalence of *Enterococcus* spp., Resistance Profiles, the Presence of the VanA and VanB Resistance Genes in Chicken Meats. *Kocatepe Veterinary Journal* Vol. 15(4), Pp. 381-389.
- Yadav, G., Thakuria, B., Madan, M., Agwan, V., Pandey, A., 2017. Linezolid and Vancomycin Resistant *Enterococci*: A Therapeutic Problem - PubMed. *Journal of Clinical And Diagnostic Research: JCDR* Vol. 11(8), Pp. GC07-GC11.
- Yoshino, Y., 2023. *Enterococcus casseliflavus* Infection: A Review of Clinical Features and Treatment. *Infect Drug Resist* Vol. 16, 363–368.
- Zaheer, R., Cook, S.R., Barbieri, R., Goji, N., Cameron, A., Petkau, A., Polo, R.O., Tymensen, L., Stamm, C., Song, J., Hannon, S., Jones, T., Church, D., Booker, C.W., Amoako, K., Van Domselaar, G., Read, R.R., McAllister, T.A., 2020. Surveillance of *Enterococcus* spp. Reveals Distinct Species and Antimicrobial Resistance Diversity Across A One-Health Continuum. *Sci Rep* Vol.10(1), Pp. 3937.